Friday,DECember 10, 2021


Neuromodulation in the management of heart failure and its comorbidities: diabetes, sleep apnea and hypertension

08:00 - 10:00  |  Ballroom

Translational concepts in the development of new treatment strategies     
Renal denervation for heart failure treatment: Renal denervation for HFpEF: trial design considerations - how can RDN learn from trials of inter-atrial shunt trials and SGLT-2 inhibitors     
Renal denervation for heart failure treatment: Renal denervation for HFrEF: how to design trials given all the other treatments available - where would RDN fit in this crowded space?     
Treatment of central sleep apnea in heart failure patients: Remede     
Update on electrical barostimulation     
Stent-based barostimulation: Results of the first in man trial     
An endovascular approach for treating HF patients using an implantable active Neuromodulation Implant     
Metavention: Renal and hepatic artery denervation to treat metabolic syndrome     
Vagus nerve stimulation     
Atrial fibrillation in heart failure

Pathogenesis and treatment of heart failure with preserved ejection fraction (HFpEF)

10:30 - 11:20  |  Ballroom

What are the underlying causes of HFpEF     
The many faces of HFpEF – not just one disease     
The failures, the learnings and the encouraging future - overview of potential therapies for HFpEF (medical therapy, clinical trial design, devices)     
What is the causal role for Tricuspid Regurgitation in HFpEF?

The splanchnic bed is a novel target in patients with heart failure with preserved ejection fraction (HFpEF) s

11:20 - 12:35  |  Ballroom

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF     
Long-term follow-up on FIH endovascular therapy using the Satera Ablation System in HFpEF and HFrEF     
Where does this therapy potentially fit into current landscape of treatments for HFpEF and HFrEF
Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF     
Proposed design of the worldwide Pivotal Clinical HF trial


12:50 - 14:00  |  Ballroom

Telemedicine advancements during the COVID-19 pandemic: What's worked, what hasn't, and what's to come?     
Non-invasive assessment of lung fluid content     
Implantable Hemodynamic Monitors: CardioMEMS…     
Implantable Hemodynamic Monitors: The first in heart microcomputer for the management of HF patients     
Implantable Hemodynamic Monitors: Exercise stress testing in remote heart failure management     
Non-invasive assessment of fluid status and arrthymogenic     
Payer perspective

Durable mechanical circulatory support

14:00 - 15:10  |  Ballroom

Durable MCS state of the art     
CorWave LVAD - a biomimetic pump for physiologic pulsatility     
HeartMate 3      
Carmat Aeson LVAD  

Impella 5.5

Impella BRT     

Cardio Dyme

Acute mechanical circulatory support

15:40 - 17:10  | Ballroom

Acute MCS state of the art     
ECP EFS     

ProtekDuo in COVID ARDS
Aortix EFS     



PreCardia EFS   

PreCardia clinical trial
New Impella RP    

Insights from the PULSE Trial & iVAC 2L in MCS facilitated high-risk PCI

New and upcoming concepts and devices

17:10 - 18:00  |  Ballroom

Synchronized diaphragmatic stimulation for the treatment of symptomatic heart failure       
Importance of mitral valve plane movement in heart pumping - updated insights     
Syntach - a novel minimally invasive cardiac support system      

Targeting enhanced decongestion while aiming to preserve renal function – lymphatic-powered interstitial decongestion     
Percutaneous Pericardial Resection

Device Development Workshop

18:00 - 19:00  |  Ballroom



Saturday, DECember 11, 2021


E-poster presentation

07:00 - 08:00  |  Exhibition area


Electrotherapy for heart failure treatment

08:00 - 08:40  |  Ballroom

Cardiac contractility modulation     
CCM – Closing the gap: When OMT is not enough     
HIS Bundle stimulation     
New results from the landmark REVERSE trial: More patients may benefit from CRT therapy

Interventions for LV Reconstruction and support

08:40 - 09:40  |  Ballroom

Therapeutic opportunity & single center experience     
Predictors of Revivent LV restoration outcomes     
The AccuCinch Ventricular Restoration System     
Transcatheter intramyocardial hydrogel injection (XDrop): FIM results     
Percutaneous radiofrequency ablation of HOCM

Right heart failure

0940 - 10:50  |  Ballroom

Pathology and pathophysiology, clinical  relevance of RHF-does it help to treat TR?     
Evaluation of right ventricular function and its importance in RHF     
Right heart failure in the guidelines     
Mechanical assist in RHF using Impella RP     
Mechanical assist in RHF using the PERKAT RV pulsatile right ventricular support device     
PHT in RHF, monitoring and treatment     
Tricuspid trial for RHF: Haemodynamic perspective

Valve interventions in patients with heart failure

10:20 - 12:50  |  Ballroom

Recent innovations for the management of patients with valvular heart disease – focus on heart failure     
2021 European guidelines on heart failure – focus on heart valves     
Echo criteria to identify TEER responders beyond COAPT     
Volume outcome relation in percutaneous FMR treatment     
Role of the right sided heart in FMR     
The impact of tricuspid regurgitation on patient outcomes     
What do the guidelines say about tricuspid regurgitation?     
Status on transcatheter tricuspid valve interventions – when & how     
The current evidence and the vast clinical study & registry pipeline     
Case presentation: improving patient outcomes and QoL with a new device (PASCAL Ace)     
Prevalence, prognosis, and management of exercise-induced severe MR in patients with heart failure     
Closing remarks

Interatrial shunts

13:35 - 15:30  |  Ballroom

The physiological rationale for IASD as a treatment for heart failure     
Lessons learned and being learned from the Corvia Reduce LAP-2 Study     
IASD across the spectrum of EFs     
Are different size shunts required?     
Is a device implant necessary for effective interatrial shunt?     
Alternate means of creating a durable shunt without leaving a device behind: Noya     
Alternate means of creating a durable shunt without leaving a device behind: InterShunt     
Interatrial shunting for pulmonary hypertension     
Clinical trial considerations for IASD pivotal studies     
Interatrial shunt for end-stage amyloid heart disease (recorded case)

The future of device-based therapies and diagnostics for heart failure

16:00 - 17:20  |  Ballroom

CMO View
Cardiovascular innovations in Corona time     
We now have a drug therapy which is effective in HFpEF: Do we still need a device based therapy

I am confused! Out of these 50+ treatment options – when to use what?

17:20 - 18:00   |  Ballroom

Case 1
Case 2
Case 3
Case 4